SEC Form 4 · accession 0001437749-19-000188
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Stanley Rosol
Officer — Chief Medical Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 3, 2019 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $0.38 | Jan 2, 2019 | A | 125,000 | A | — | Jan 2, 2029 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F141,667 options will be exercisable on or after 1/2/2019; 41,667 options will be exercisable on or after 7/2/2019; and 41,666 options will be exercisable on or after 1/2/2020.